EyePoint Pharmaceuticals (EYPT) opened 2026 with Q1 revenue of US$0.7 million, a basic EPS loss of US$0.99 per share and a net income loss of US$84.8 million, setting a clear tone for how profitability is tracking into the new year. The company has seen quarterly revenue move from US$24.5 million in Q1 2025 to US$0.7 million in Q1 2026, while quarterly basic EPS shifted from a loss of US$0.65 to a loss of US$0.99. The latest print keeps the focus squarely on how much cash the business is burning to pursue its growth plans and how margins are holding up against that backdrop.

See our full analysis for EyePoint.

With the latest numbers on the table, the next step is to see how this earnings profile lines up with the widely shared growth and risk narratives around EyePoint and where those storylines might need a reset.

Losses widen to US$84.8 million on a much smaller top line

• Net income loss over the last twelve months reached US$271.6 million on US$7.6 million of revenue, compared with a Q1 2026 loss of US$84.8 million on US$0.7 million of revenue, so the company is currently running at very high losses relative to its sales base.
• Consensus narrative points to potential future revenue streams from DURAVYU in large retinal markets. However, the recent move from US$24.5 million of quarterly revenue in Q1 2025 to under US$1 million a year later keeps the focus squarely on whether those hoped for approvals and commercial launches can realistically support this level of spending.

Cash runway under a year against ongoing Q1 scale losses

• The latest trailing twelve month loss of US$271.6 million sits alongside an assessment that cash runway is under one year. This means the current rate of spending is a key constraint even before any additional launch costs are layered in.
• Bears argue that a business model producing US$63 million of quarterly operating expenses alongside about US$0.7 million of revenue will likely need more funding, and that this could dilute shareholders further if DURAVYU milestones slip or if commercialization requires heavier investment than currently expected.
  • This concern lines up with the recent pattern of widening losses, from US$41.4 million in Q4 2024 to US$84.8 million in Q1 2026, without a corresponding revenue offset.
  • With less than one year of cash runway highlighted as a risk, the cautious view treats any delay in converting the pipeline into revenue as directly feeding into future capital raise needs.

On these numbers, skeptics see the Q1 profile as a stress test of EyePoint's ability to fund its plans without significant further dilution, and they lean on that concern when weighing the more cautious narrative for DURAVYU. 🐻 EyePoint Bear Case

Rich P/B at 4.9x despite share price below DCF fair value

• At a share price of US$13.35, the stock is reported to trade on a P/B of 4.9x versus peer and industry averages of 2.4x and 2.7x, even though it is also flagged as trading well below a DCF fair value of US$56.61.
• Bullish investors point to forecast revenue growth of around 58.8% per year and the gap between the US$13.35 share price and both the US$37.17 analyst target and the US$56.61 DCF fair value. Yet the same data show that the company is still loss making with a trailing twelve month EPS of US$3.51 loss and is not forecast to be profitable over the next three years, so the optimistic view has to reconcile those valuation markers with sustained red ink.
  • The wide spread between the current price and DCF fair value heavily supports the bullish case that the market may be underpricing long term cash flows, assuming the growth narrative plays out.
  • At the same time, a P/B that already sits well above peers challenges the idea that the stock is cheap on every metric, especially while net losses have grown from US$130.9 million to US$271.6 million over the last few years of trailing data.

If you want to see how those bullish expectations tie back to detailed revenue and earnings paths, it is worth looking through the full bull case for EyePoint. 🐂 EyePoint Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for EyePoint on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With sentiment clearly split between the risks of sustained losses and the potential rewards tied to the pipeline, it makes sense to check the numbers yourself and move quickly if you see something the market is missing, starting with the 2 key rewards and 3 important warning signs.

See What Else Is Out There

EyePoint is carrying heavy losses on a very small revenue base, with an assessed cash runway under one year and questions around future funding needs.

If you are worried about that level of pressure on the balance sheet and want stocks where financial strength is a clearer starting point, the solid balance sheet and fundamentals stocks screener (46 results) can quickly surface ideas with sturdier fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.